Fig. 2: Conditions that need to be met for MRD state to be a perfect surrogate for relapse risk when running clinical trials to compare efficacy of protocols.
From: Measurable residual disease (MRD)-testing in haematological and solid cancers
To be able to use MRD state as a surrogate for cumulative incidence of relapse (CIR) when comparing protocols in clinical trials, it is crucial that MRD-test results have the same implications for CIR and follow-up interventions (or lack thereof) regardless of which protocol (A versus B) is used prior to the MRD-test. More explanations are available in Supplementary Methods.
